Purpose of the Assay
- Determine the likelihood of breast cancer recurrence within 10 years.
- Predict whether chemotherapy will be beneficial for the patient.
- Enable a personalized treatment plan based on the tumor's genetic profile.
Book Oncotype DX Test in Saudi Arabia | Lahalak Medical Platform
The Oncotype DX assay provides personalized insights into your breast cancer treatment. By analyzing gene expression, it predicts recurrence risk and chemotherapy benefit, helping you and your doctor choose the safest path.
Scientific name: Oncotype DX Breast Cancer Assay
A genomic test analyzing 21 genes in breast cancer tissue to calculate a recurrence score. It predicts cancer return risk and chemotherapy effectiveness, enabling personalized and precise treatment plans.
Service type
Oncologic Genomic Test
Duration
14-21 working days
Fasting
Fasting is not required
Included Services
- 21-gene expression analysis
- Recurrence Score report
- Chemotherapy benefit assessment
Medical Service Information
Target Groups
- Patients diagnosed with early-stage breast cancer (Stage I or II).
- Hormone receptor-positive (HR+) tumor cases.
- HER2-negative breast cancer cases.
Understanding the Results
- Low Recurrence Score (0-25): Low risk of return; chemotherapy benefit is usually minimal.
- High Recurrence Score (26-100): Higher risk of return; chemotherapy is likely to be beneficial.
Conditions & Notices
- Requires a preserved tissue sample from the tumor (biopsy or surgery)
- Typically for patients with early-stage breast cancer
Medical services you might also like
